Group 1: Company Strategy - The company focuses on the "big health" development strategy in pharmaceuticals and medical services, aiming to create a comprehensive health ecosystem covering the entire lifecycle of customers [2] - It aims to enhance core competitiveness by concentrating on its main business and improving management levels across various sectors [3] Group 2: Financial Performance - The company forecasts a net profit attributable to shareholders for 2025 between CNY 660 million and CNY 730 million, representing a year-on-year growth of 320.74% to 344.16% [2] - The net profit after deducting non-recurring gains and losses is expected to be between CNY 600 million and CNY 670 million, indicating a growth of 277.59% to 298.31% compared to the previous year [2] Group 3: Pharmaceutical Business - The pharmaceutical segment includes the development, production, and sales of drug formulations and active pharmaceutical ingredients (APIs), with a focus on skin, anti-infection, and anti-tumor products [4] - The company has established three major API production bases, ensuring a stable supply of core products and achieving integration of API and formulation production [4] Group 4: Research and Development - The company emphasizes R&D in pharmaceuticals, focusing on generic drugs in dermatology and specialty medications, while also investing in innovative drugs through its subsidiary [5] - It holds a 13.2% stake in a company specializing in cell gene therapy, making it the third-largest shareholder [5] Group 5: Medical Services - The company has developed a layered business ecosystem in healthcare, providing integrated medical services that include basic medical care, rehabilitation, and longevity health services [6] - It operates hospitals and health management centers, focusing on disease treatment and health improvement [6][7] Group 6: Health Management - The company has established three longevity and anti-aging centers in major cities, implementing a comprehensive management system for health assessment and intervention [7] - It has partnered with global anti-aging pioneer Bryan Johnson to launch the "Blueprint" anti-aging brand, enhancing its service offerings [8] Group 7: Shareholder Returns - The company has maintained a high dividend policy, distributing approximately CNY 3 billion since 2018, and plans to continue sustainable profit distribution [9] - It is considering diverse dividend methods in the future based on its financial performance [9] Group 8: Bond Issuance - The company plans to issue exchangeable bonds totaling no more than CNY 1 billion, subject to market conditions and shareholder approval [9]

Group 1 - The company Huabang Health announced that its performance forecast for the fiscal year 2025 was disclosed on January 20, 2026 [2]

Group 1 - The company, Huabang Life Health Co., Ltd., has received notification from its controlling shareholder, Chongqing Huabang Zhuoyuan Technology Co., Ltd., regarding the release of part of its pledged shares [1] - As of the announcement date, the cumulative pledge situation of shares held by Huabang Zhuoyuan and its concerted actors, including Mr. Zhang Songshan, Mr. Zhang Yizhuo, and Ms. Zhao Danlin, is detailed [1] - The announcement includes reference to documents such as the "Securities Pledge and Judicial Freezing Details" issued by China Securities Depository and Clearing Corporation Limited [1]

Group 1 - The core point of the announcement is that Huabang Life Health Co., Ltd. has received notification from its controlling shareholder, Chongqing Huibang Zhuoyuan Technology Co., Ltd., regarding the release of a portion of its pledged shares [1] - The announcement includes details about the basic situation of the share pledge release [1] - As of the date of the announcement, the total pledged shares held by Huibang Zhuoyuan and its concerted actors, including Mr. Zhang Songshan, Mr. Zhang Yizhuo, and Ms. Zhao Danlin, are outlined [1] Group 2 - The announcement references specific documents related to the share pledge, including the stock pledge repurchase agreement and statements from the China Securities Depository and Clearing Corporation [2] - The board of directors of Huabang Life Health Co., Ltd. confirms the accuracy and completeness of the information disclosed [1][3] - The announcement is officially issued by the board of directors on January 23, 2026 [4]

证券代码：002004 证券简称：华邦健康 公告编号：2026006 华邦生命健康股份有限公司 关于控股股东部分股份解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特此公告。 华邦生命健康股份有限公司 | 股东 | 是否为控股股东或第一大 | 本次解除质押股 | 占其所持股份 | 占公司总股 | 质押起始日 | 解除质押日期 | 质权人 | | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 股东及其一致行动人 | 份数量（股） | 比例 | 本比例 | | | | | 汇邦卓远 | 是 | 10,600,000 | 2.86% | 0.54% | 2023.05.31 | 2026.01.21 | 中信建投证券 股份有限公司 | 二、汇邦卓远及其一致行动人股份累计质押基本情况 截至本公告披露日，汇邦卓远及其一致行动人张松山先生、张一卓先生、赵 丹琳女士所持股份质押情况如下： | | 持股数量 | | 累计质押数量 | 占其所持 | 占公司 | 已质押股份情况 | | 未质押股份情况 ...

Group 1 - The controlling shareholder Huibang Zhuoyuan has notified that it will release the pledge of 10.6 million shares, which accounts for 2.86% of its holdings and 0.54% of the company's total share capital [1] - The pledge was initiated on May 31, 2023, and is set to be released on January 21, 2026 [1] - As of the announcement date, Huibang Zhuoyuan and its concerted actors have a total of 254 million shares pledged, representing 46.80% of their holdings and 12.83% of the company's total share capital [1]

Group 1: Profit Forecasts - Limin Co. expects a net profit of 465 million to 500 million yuan for 2025, representing a year-on-year increase of 471.55% to 514.57% [1] - Guohui Energy anticipates a net profit of 1.32 billion to 1.47 billion yuan for 2025, reflecting a decline of 50.03% to 55.13% year-on-year [2] - Jiajia Yue forecasts a net profit of 198 million to 228 million yuan for 2025, indicating a growth of 50.06% to 72.79% year-on-year [3] - Xianghe Industry projects a net profit of 120 million to 148 million yuan for 2025, with an expected increase of 59.17% to 96.31% year-on-year [4] - Aojie Technology predicts a net profit of 90 million to 120 million yuan for 2025, showing a growth of 228.34% to 337.79% year-on-year [14] - Shanghai Electric expects a net profit of 1.1 billion to 1.32 billion yuan for 2025, representing an increase of approximately 47% to 76% year-on-year [15] - Tianfu Communication anticipates a net profit of 1.881 billion to 2.15 billion yuan for 2025, reflecting a growth of 40% to 60% year-on-year [16] - Yichang Technology forecasts a net profit of 150 million to 225 million yuan for 2025, indicating a year-on-year increase of 58% to 138% [29] - Shanghai Yizhong expects a net profit of 60 million to 70 million yuan for 2025, representing a significant increase of 760.18% to 903.54% year-on-year [41] Group 2: Loss Forecasts - Kexin Electromechanical anticipates a net profit of 55 million to 70 million yuan for 2025, reflecting a decline of 58.65% to 67.51% year-on-year [11][12] - Kexin Technology expects a net loss of 900 million to 1.2 billion yuan for 2025, which is an increase in loss of 78.67% to 84% year-on-year [10] - Tianyang New Materials forecasts a net loss of 250 million to 180 million yuan for 2025, compared to a loss of 213 million yuan in the previous year [20] - Bo Rui Data anticipates a net loss of 90 million to 100 million yuan for 2025, which is an increase in loss of 15.17 million to 25.17 million yuan year-on-year [19] - Xinlian Integrated expects a net loss of 577 million yuan for 2025, which is a reduction in loss of approximately 40.02% compared to the previous year [40] - Fangshilong forecasts a net loss of 4 million to 6 million yuan for 2025 [30] Group 3: Strategic Developments - Lianlong signed a strategic framework agreement with Runyinglian to enhance the reliability and efficiency of the lubricant additive supply chain in China and the Asia-Pacific region [7] - Han Jian Heshan is planning to acquire a 52.51% stake in Liaoning Xingfu New Materials Co., Ltd., with stock suspension expected for up to 9 trading days [13] - Kai Zhong Precision plans to invest 116 million yuan in a technical transformation and expansion project to meet future capacity demands [34] - Tianfu Communication is expected to engage in clinical trials for its ABA001 injection, which has received approval from the National Medical Products Administration [17]

Core Viewpoint - Huabang Health (002004) expects a net profit attributable to shareholders of 660 million to 730 million yuan for the fiscal year 2025, representing a significant increase of 320.74% to 344.16% compared to a loss of 299 million yuan in the same period last year [1] Group 1: Financial Performance - The projected net profit for 2025 is between 660 million and 730 million yuan [1] - This marks a growth of 320.74% to 344.16% from the previous year's loss of 299 million yuan [1] Group 2: Business Segments - The agricultural chemical materials sector has shown signs of partial recovery during the reporting period [1] - The pharmaceutical and tourism sectors have also achieved steady growth, contributing to the overall performance improvement [1]

Core Viewpoint - Huabang Health (002004) is expected to report a significant increase in net profit for the year 2025, with projections indicating a growth of 320.74% to 344.16% compared to the previous year [1] Financial Performance - The anticipated net profit for 2025 is estimated to be between 660 million to 730 million yuan [1] - The net profit excluding non-recurring gains and losses is projected to be between 600 million to 670 million yuan, reflecting a year-on-year growth of 277.59% to 298.31% [1]

Group 1: Delisting Risks - *ST Xin Yan: The Shenzhen Stock Exchange has approved the company's application to revoke the delisting risk warning due to restructuring [1] - *ST Zhong Zhuang (Rights Protection): The delisting risk warning has been revoked, but other risk warnings will continue, and the stock will be suspended for one day starting tomorrow [2] - ST Sai Wei: Expected to incur a loss of 720 million to 1.02 billion yuan in 2025, with a possibility of being subject to delisting risk warnings [3] Group 2: Earnings Forecasts - Hikvision: Expected net profit attributable to shareholders to grow by 18.46% year-on-year in 2025 [28] - Langzi Co.: Expected net profit to increase by 245.25% to 302.8% year-on-year in 2025 [4][30] - Zhaoyan New Drug: Expected net profit to increase by 214% to 371% year-on-year in 2025 [5][30] - Huachen Equipment: Expected net profit to increase by 193.64% to 242.04% year-on-year in 2025 [6][30] - Qianyuan Power: Expected net profit to increase by 160% to 190% year-on-year in 2025 [7][30] - Jin Fang Energy: Expected net profit to increase by 123.97% to 193.7% year-on-year in 2025 [8][31] - Zhongfu Industrial: Expected net profit to increase by 120.27% to 141.59% year-on-year in 2025 [9][32] - Batian Co.: Expected net profit to increase by 117.53% to 139.53% year-on-year in 2025 [10][32] - Zhongrong Electric: Expected net profit to increase by 104.89% to 131.10% year-on-year in 2025 [11][32] - Kaisheng New Materials: Expected net profit to increase by 96.47% to 150.06% year-on-year in 2025 [12][32] - Putailai: Expected net profit to increase by 93.18% to 101.58% year-on-year in 2025 [13][32] - Dongfang Iron Tower: Expected net profit to increase by 91.4% to 125.07% year-on-year in 2025 [14][32] - Pulaike: Expected net profit to increase by 89.64% to 110.11% year-on-year in 2025 [15][32] - Huabang Health: Expected profit of 660 million to 730 million yuan in 2025, turning from loss to profit [16][32] - Hongyuan Green Energy: Expected net profit of 180 million to 250 million yuan in 2025, turning from loss to profit [17][32] - Kangda New Materials: Expected profit of 125 million to 135 million yuan in 2025, turning from loss to profit [18][32] - Langxin Technology: Expected profit of 100 million to 150 million yuan in 2025, turning from loss to profit [19][32] - Hualv Biological: Expected profit of 100 million to 130 million yuan in 2025, turning from loss to profit [20][32] Group 3: Mergers and Acquisitions - Kangxin New Materials: Plans to acquire 51% of Yubang Semiconductor for 392 million yuan [21][32] - Aibo Medical: Plans to gain control of Demei Medical [22][32] Group 4: Share Buybacks and Reductions - Hengtong Co.: Plans to repurchase company shares worth 80 million to 100 million yuan [24][32] - Haier Smart Home: Plans to repurchase D shares up to 200,000 euros [29][32] - Blue Universe Co.: Shareholders plan to reduce their holdings by no more than 3.02% [29][32] - Hesheng Silicon Industry: Controlling shareholder plans to reduce holdings by no more than 3% [29][32] - Aolian Electronics (Rights Protection): Shareholder Liu Junsheng plans to reduce holdings by no more than 3% [29][32] - Bluefeng Biochemical: Hainan Wenqin plans to reduce holdings by no more than 3% [29][32] - Zhixin Precision: Shareholders plan to reduce holdings by no more than 3% [29][32] - Peking University Medical: Peking University Health plans to reduce holdings by no more than 3% [29][32] Group 5: Other Updates - Liou Co.: Self-inspection work has been completed, and the stock will resume trading on January 21 [29][32] - Yongxing Materials: The lithium mica green intelligent and efficient lithium extraction project has reached production capacity [29][32] - Debang Co.: Plans to voluntarily withdraw A shares from trading on the Shanghai Stock Exchange [29][32]